Clinicians (n = 43) | Parents (n = 27) | |||||
---|---|---|---|---|---|---|
Outcome | Rank ( n /17) | Median (IQR) | Number (%) scoring outcome in top 3 | Rank | Median (IQR) | Number (%) scoring outcome in top 3 |
Quality of Life | 1 | 4 (3, 4) | 20 (47) | 2 | 4 (4, 4) | 9 (33) |
Exacerbations | 2 | 4 (4, 4) | 18 (42) | 3 | 4 (4, 4) | 9 (33) |
Nocturnal symptoms | 3 | 4 (4, 4) | 16 (37) | 4 | 4 (4, 4) | 8 (30) |
Normal activities | 4 | 4 (4, 4) | 12 (28) | 8= | 4 (4, 4) | 4 (15) |
Daytime symptoms | 5 | 4 (4, 4) | 11 (26) | 6 | 4 (4, 4) | 6 (22) |
Death | 6 | 4 (2, 4) | 11 (26) | 1 | 4 (4, 4) | 14 (52) |
Use of reliever inhaler | 7 | 4 (3, 4) | 9 (21) | 10 | 4 (3, 4) | 3 (11) |
Hospital admission | 8 | 4 (3, 4) | 8 (19) | 12 | 4 (4, 4) | 2 (7) |
Activity or exercise | 9 | 4 (3, 4) | 7 (16) | 5 | 4 (3, 4) | 7 (26) |
Long-term adverse effect | 10 | 4 (4, 4) | 7 (16) | 8= | 4 (4.4) | 4 (15) |
School attendance | 11 | 4 (3, 4) | 7 (16) | 11 | 4 (4, 4) | 2 (7) |
Parent/child global assessment of control | 12 | 4 (3, 4) | 7 (16) | 14 | 4 (3, 4) | 2 (7) |
Lung function tests | 13 | 3 (2, 3) | 5 (12) | 15 | 4 (3, 4) | 1 (4) |
GP/A + E attendance | 14 | 4 (3, 4) | 3 (7) | 16 | 4 (3, 4) | 0 |
Growth | 15 | 4 (3, 4) | 2 (5) | 13 | 4 (3, 4) | 2 (7) |
Health-related problems when older | 16 | 3 (2, 4) | 0 | 7 | 4 (4, 4) | 5 (19) |
Short-term adverse effect | 17 | 3 (2, 3) | 0 | 17 | 4 (3, 4) | 0 |